CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

BRII-196Wiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (3)

Name (Synonyms) Correlation
drug497 CAG length >=22 Wiki 1.00
drug496 CAG length <22 Wiki 1.00
drug2122 Placebo Wiki 0.05

Correlated MeSH Terms (1)

Name (Synonyms) Correlation
D000505 Alopecia NIH 0.71

Correlated HPO Terms (1)

Name (Synonyms) Correlation
HP:0002293 Alopecia of scalp HPO 0.71

There is one clinical trial.

Clinical Trials

1 A Phase 1 Randomized, Single-blind, Placebo-controlled, Single Ascending Dose Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Human Monoclonal Antibody, BRII-196 Administered Intravenously to Healthy Adult Volunteers

This is a phase 1 study in which healthy adult volunteers will receive BRII-196 or placebo and will be assessed for safety, tolerability, and pharmacokinetics.

NCT04479631 COVID-19 Drug: BRII-196 Drug: Placebo

Primary Outcomes

Measure: Incidence of adverse events (AEs) by CTCAE v5.0

Time: up to 24 weeks

Measure: Proportion of subjects with SAEs

Time: up to 24 weeks

Measure: Proportion of subjects with infusion-related reactions

Time: up to 24 weeks

Measure: Proportion of subjects with hypersensitivity reactions

Time: up to 24 weeks

Secondary Outcomes

Measure: Serum Concentration of BRII-196

Time: up to 24 weeks

No related HPO nodes (Using clinical trials)